<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33526">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01970319</url>
  </required_header>
  <id_info>
    <org_study_id>14606</org_study_id>
    <nct_id>NCT01970319</nct_id>
  </id_info>
  <brief_title>Mechanisms and Reversibility of Heart Failure Associated With Diabetes</brief_title>
  <acronym>MRHD</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Peter Swoboda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <authority>United Kingdom: National Institute for Health Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with diabetes have a higher incidence of heart failure and worse outcomes than
      normoglycaemic subjects. Basic science research has suggested many mechanisms for this
      observation including endothelial dysfunction, abnormal calcium handling, fibrosis and
      activation of the renin-angiotensin-aldosterone system (RAAS), but clinical data are
      lacking. In this study the investigators will investigate the relationship between diabetes
      and heart failure by exploring the correlation between microvascular dysfunction and cardiac
      magnetic resonance (CMR) markers of left ventricular (LV) hypertrophy, cardiac dysfunction
      and fibrosis. The investigators also propose to see if this relationship is independent of
      blood pressure and markers of RAAS activity. This could have important clinical
      ramifications in type 2 diabetes by increasing the indications for treatment with RAAS
      inhibition or making a case for lower blood pressure targets.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Left ventricle mass</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricle function</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAAS activity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Diabetic with nephropathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetics without nephropathy</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Frozen serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care patients with type 2 diabetes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

        Exclusion Criteria:

          -  Known cardiac or renal disease

          -  Uncontrolled hypertension

          -  Treatment with ACEi/ARB

          -  Treatment with insulin

          -  Contraindication to CMR
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Swoboda, MBBS</last_name>
    <email>p.swoboda@leeds.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Swoboda, MBBS</last_name>
      <email>p.swoboda@leeds.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=14606</url>
  </link>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 25, 2013</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>Dr. Peter Swoboda</investigator_full_name>
    <investigator_title>BHF Clinical Research Training Fellow</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
